Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology  TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported improvement in facial vitiligo, with half reporting “much’ or “very much” improved TEV-’408 is designed for convenient quarterly (Q12W) subcutaneous dosing Teva will hold […]